SureTrader
Interactive Brokers Advertisement
SureTrader
Home > Boards > US Listed > Biotechs >

Cel-Sci (CVM)

CVM RSS Feed
Add CVM Price Alert      Hide Sticky   Hide Intro
Moderator: mick, Foxwoods Man, drkazmd65
Search This Board: 
Last Post: 6/24/2017 1:54:34 PM - Followers: 190 - Board type: Free - Posts Today: 2

 Cel-Sci Corporation (CVM)

http://www.cel-sci.com/

https://www.youtube.com/watch?v=auAihG3rtC4

Products In Development

Multikine® (Leukocyte Interleukin, Injection) is the full name of this investigational therapy, which, for simplicity, is referred to in the remainder of this page as Multikine*.

CANCER - MULTIKINE

Multikine, CEL-SCI's lead investigational immunotherapy, is an immunotherapeutic agent that is being developed as a potential first-line treatment for advanced primary head and neck cancer. If it were to be approved for use following completion of CEL-SCI's clinical development program, Multikine would be a different kind of therapy in the fight against cancer; one that appears to have the potential to work with the body's natural immune system in the fight against tumors.

Multikine may also have the potential to be a first in a new class of cancer immunotherapy drugs. It is the first investigational combination immunotherapy thought to have both passive and active immune properties.  More...

INFECTIOUS DISEASES - L.E.A.P.S.(TM)**

L.E.A.P.S is a patented, T-cell modulation, peptide epitope delivery technology that enables CEL-SCI to design and synthesize proprietary peptide immunogens. L.E.A.P.S. compounds consist of a small T-cell binding peptide ligand linked with a disease-associated peptide antigen.

This new technology has been shown the potential in several animal models to preferentially direct immune response to a cellular (e.g., T-cell), humoral (antibody) or mixed pathway. Diseases for which antigenic epitope sequences have been identified, such as some infectious diseases, cancer, autoimmune diseases, allergic asthma and allergy, and select CNS diseases (e.g., Alzheimer's) may be potential candidates for development using this technology platform.  More...

 

* Multikine is the trademark that CEL-SCI has registered for this investigational therapy, and this proprietary name is subject to FDA review in connection with our future anticipated regulatory submission for approval. Multikine has not been licensed or approved for sale, barter or exchange by the FDA or by any other regulatory agency. Similarly, its safety of efficacy has not been established for any use. Moreover, no definitive conclusions can be drawn from the early-phase, clinical-trials data summarized on this page or elsewhere on this website involving the investigational therapy Multikine (Leukocyte Interleukin, Injection). Further research is required, and early-phase clinical trial results must be confirmed in the well-controlled, Phase III clinical trial of this investigational therapy that is currently in progress.

** L.E.A.P.S. is the trademark of CEL-SCI for this investigational platform technology, and this proprietary name is subject to FDA review. No L.E.A.P.S. product has been approved for sale, barter or exchange by the FDA or any other regulatory agency for any use to treat disease in animals or humans. The safety or efficacy of these products has not been established for any use. Lastly, no definitive conclusions can be drawn from these early-phase, preclinical-trials data involving these investigational products

Partnering Philosophy & Corporate Partners

CEL-SCI's partnering philosophy is guided by the belief that any partnership entered into should serve the best interests of: 

  1. The patients who are/will be treated,
    The scientific, clinical, and commercial development of the medicine and
    CEL-SCI's shareholders.

CEL-SCI is open to any reasonable partnership proposals that will accelerate its being able to bring its medicines to market.

Multikine® (Leukocyte Interleukin, Injection):

Multikine (Leukocyte Interleukin, Injection) is the full name of this investigational therapy, which, for simplicity, is referred to in the remainder of this page as Multikine*.

CEL-SCI has a unique expertise in the development and manufacture of complex biologics. CEL-SCI is not a company that markets and sells drug products at the current time. Regardless, CEL-SCI believes it will be capable of marketing and selling Multikine on its own for head and neck cancer in both the United States and Europe if and once it is approved by the FDA (or EU regulators). Since its primary target is head & neck cancer surgeons, a rather small audience, CEL-SCI does not believe that a large sales force will be needed to commercialize Multikine, if and once it is approved by the FDA (or EU regulators) following the review of the total Multikine Biologics License Application.

Current Corporate Partners:

  1. Byron Biopharma
     
      a. Agreement Signed March 2009  
      b. Territory - Republic of South Africa  
      c. Revenue Share  

    Teva Pharmaceuticals Industries Ltd.
     
      a. Agreement Signed August 2008  
      b. Territory - Israel, Turkey, expanded to also cover Serbia and Croatia in August 2011.  
      c. Revenue Share  
      d. Website - http://www.tevapharm.com/  

     
    Orient Europharma Co. Ltd.
     
      a. Agreement Signed November 2000  
      b. Territory - Taiwan, Singapore, Hong Kong, Malaysia, expanded to also cover South Korea, the Philippines, Australia and New Zealand in the Fall of 2008.  
      c. Revenue Share  
      d. Website - http://www.oep.com.tw/  

     
    IDC-GP Pharm LLC 
     
      a. Agreement signed August 2011  
      b. Territory - Argentina and Venezuela  
      c. Revenue Share  
      d. Website - http://www.gp-pharm.com/  

     

Other Partnering Possibilities:

Based on the Company's L.E.A.P.S.TM** technology, as long as a disease epitope is available, CEL-SCI may be able to develop an effective treatment/vaccine using the L.E.A.P.S. technology.  The two leading candidates derived from this technology are the H1N1 treatment being developed as a possible treatment option for hospitalized patients and the Rheumatoid Arthritis treatment vaccine currently being tested in animal models of the disease.

 

* Multikine is the trademark that CEL-SCI has registered for this investigational therapy, and this proprietary name is subject to FDA review in connection with our future anticipated regulatory submission for approval. Multikine has not been licensed or approved for sale, barter or exchange by the FDA or any other regulatory agency. Similarly, its safety or efficacy has not been established for any use. Moreover, no definitive conclusions can be drawn from the early-phase, clinical-trials data summarized on this page or elsewhere on this website involving the investigational therapy Multikine (Leukocyte Interleukin, Injection). Further research is required, and early-phase clinical trial results must be confirmed in the well-controlled, Phase III clinical trial of this investigational therapy that is currently in progress.

** L.E.A.P.S. is the trademark of CEL-SCI for this investigational platform technology, and this proprietary name is subject to FDA review. No L.E.A.P.S. product has been approved for sale, barter or exchange by the FDA or any other regulatory agency for any use to treat disease in animals or humans. The safety or efficacy of these products has not been established for any use. Lastly, no definitive conclusions can be drawn from these early-phase, preclinical-trials data involving these investigational products.




http://stockcharts.com/freecharts/gallery.html?CVM

http://finance.yahoo.com/q?s=cvm&ql=1

http://stockcharts.com/h-sc/ui?s=CVM&p=D&yr=3&mn=0&dy=0&id=p60195179833

 

CVM
Current Price
Volume:
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
CVM News: Statement of Changes in Beneficial Ownership (4) 06/23/2017 07:14:27 AM
CVM News: Current Report Filing (8-k) 06/22/2017 11:45:38 AM
CVM News: Current Report Filing (8-k) 06/15/2017 06:03:20 AM
CVM News: Current Report Filing (8-k) 06/13/2017 06:02:30 AM
CVM News: CEL-SCI Announces Reverse Stock Split 06/12/2017 04:00:00 PM
PostSubject
#8718  Sticky Note Do with this information what you will,... I drkazmd65 09/26/16 01:49:06 PM
#7838  Sticky Note $CVM recent news/filings mick 01/18/16 02:09:58 PM
#5747  Sticky Note They keep coming!! Foxwoods Man 04/02/14 08:51:19 AM
#11487   Yes and no. Logically it doesn't make sense. learning curve 06/24/17 01:54:34 PM
#11486   Logic says there is some pressure. Why " learning curve 06/24/17 01:50:01 PM
#11485   BEATING A DEAD HORSE ? yankeesnyc27 06/23/17 01:23:44 PM
#11484   Litigation by shareholders against the company or board sea alice 06/23/17 12:34:24 PM
#11483   In order for shareholders to be successful in sea alice 06/23/17 12:19:09 PM
#11482   What happens to shareholders that sue & LOSE??? yankeesnyc27 06/23/17 11:32:54 AM
#11481   Learning Curve sea alice 06/23/17 09:41:39 AM
#11480   L/C let me get this straight your holding warfaretrader 06/23/17 09:03:04 AM
#11479   Yes sir. Ceo is playing a moral card learning curve 06/23/17 01:50:39 AM
#11478   Yep! He is trying to buy a moral learning curve 06/23/17 01:41:51 AM
#11477   Talk real math. What is the "more expensive" learning curve 06/23/17 01:34:35 AM
#11476   I didn't sell but wondering why! kpisme 06/22/17 06:47:08 PM
#11475   Shareholders need to get a grip Gert just Turney 06/22/17 04:32:40 PM
#11474   I, thank God, got out LONG ago. But RobotDroid 06/22/17 02:03:30 PM
#11473   SOOOO, when are YOU selling your shares ??? yankeesnyc27 06/22/17 01:45:55 PM
#11472   These guys have never ever helped the shareholders. RobotDroid 06/22/17 01:18:32 PM
#11471   FAITH ?? yankeesnyc27 06/22/17 01:04:04 PM
#11470   Looking better, management still has some faith it seems. trickledownfacists 06/22/17 12:58:19 PM
#11469   JUST ? yankeesnyc27 06/22/17 12:54:37 PM
#11468   So just hostile takeover protection.... trickledownfacists 06/22/17 12:39:35 PM
#11467   IMO: this is NOT about arb.... Otherwise it yankeesnyc27 06/22/17 12:35:37 PM
#11466   Affirm trickledownfacists 06/22/17 12:30:38 PM
#11465   Probably took the loan to get them to arbitration. trickledownfacists 06/22/17 12:30:21 PM
#11464   poison pill yankeesnyc27 06/22/17 12:30:08 PM
#11463   Way weird.... more to come? Still halted. trickledownfacists 06/22/17 11:55:45 AM
#11462   Agreed,... That ended up being a big 'Meehhhh,...' drkazmd65 06/22/17 11:54:55 AM
#11461   An hour hold for really nothing that huge..... trickledownfacists 06/22/17 11:50:12 AM
#11460   https://www.sec.gov/Archives/edgar/data/725363/000100487817000139/form8kitem101s trickledownfacists 06/22/17 11:49:56 AM
#11458   This halt is likely about the arbitration. It reslabrat 06/22/17 11:32:46 AM
#11457   Yup, but to play devils advocate there is trickledownfacists 06/22/17 11:30:59 AM
#11456   So assume the settlement is for $50 MM,.... drkazmd65 06/22/17 11:26:48 AM
#11455   Yup, affirm. So about 20% is a trickledownfacists 06/22/17 11:16:19 AM
#11454   I would much rather see the FDA hold steve2150 06/22/17 11:12:48 AM
#11453   From that Seeking Alpha article I wrote in drkazmd65 06/22/17 11:10:56 AM
#11452   Lake Williams will take $5 million plus 15-20 percent. trickledownfacists 06/22/17 11:05:12 AM
#11451   Affirm, watching and waiting trickledownfacists 06/22/17 10:58:59 AM
#11450   Indeed,... Must admit that I would prefer the drkazmd65 06/22/17 10:56:48 AM
#11449   Either way, it'll be really good news or trickledownfacists 06/22/17 10:55:53 AM
#11448   I thinks it has to involve one of those trickledownfacists 06/22/17 10:55:10 AM
#11447   Arbitration finally settled? FDA Hold Lifted? drkazmd65 06/22/17 10:51:35 AM
#11446   89% float shorted with 9 million shares outstanding. trickledownfacists 06/22/17 10:40:06 AM
#11445   Affirm. Halted pending news. trickledownfacists 06/22/17 10:22:35 AM
#11444   T1 Halt. GMONEY4 06/22/17 10:18:21 AM
#11443   If they expire can we stick a fork lightrock 06/21/17 03:12:27 AM
#11442   Well CVM just as to get a tad Foxwoods Man 06/20/17 03:39:22 PM
#11441   Well people are still buying the warrants. trickledownfacists 06/20/17 01:58:24 PM
#11440   The SEC has ruled that they have done trickledownfacists 06/20/17 12:35:43 PM
#11439   I wish the SEC would start throwing people Spike5 06/20/17 12:16:45 PM
#11438   I hear you, but we are in sort lightrock 06/19/17 01:07:50 PM
#11437   Did you mean to say that a $50M Trustbaby 06/19/17 12:31:05 PM
PostSubject